Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026)
Halozyme Therapeutics' Income from Continuing Operations came in at $229.9 million for Q2 2026, up 39.2% from $165.16 million a year earlier and up 53.2% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Halozyme Therapeutics reported Income from Continuing Operations of $413.56 million, down 25.8% year-over-year; for FY2025, it was $316.89 million, down 28.6% from FY2024.
- Income from Continuing Operations carries a five-year compound annual growth rate of 19.7% (FY2020 to FY2025).
- Going back by year, Income from Continuing Operations was $444.09 million in FY2024 (+57.7%), $281.59 million in FY2023 (+39.3%), $202.13 million in FY2022 (-49.8%) and $402.71 million in FY2021 (+212.0%).
- The Q2 2026 figure represents the highest quarterly Income from Continuing Operations in data going back to Q2 2010.
- The fastest year-over-year change in Income from Continuing Operations over five years came in Q3 2021 (growth of 498.2%), and the weakest in Q2 2022 (a decline of 75.2%).
- Business Quant data shows HALO's Income from Continuing Operations at $150.03 million (Q1 2026), -$141.59 million (Q4 2025) and $175.23 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Halozyme Therapeutics | 12.59 Bn | 11.20 Bn | 401.83 Mn | 229.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 229.90 Mn |
| Mar 31, 2026 | 150.03 Mn |
| Dec 31, 2025 | -141.59 Mn |
| Sep 30, 2025 | 175.23 Mn |
| Jun 30, 2025 | 165.16 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 137.01 Mn |
| Sep 30, 2024 | 137.01 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 76.82 Mn |
| Dec 31, 2023 | 85.39 Mn |
| Sep 30, 2023 | 81.84 Mn |
| Jun 30, 2023 | 74.75 Mn |
| Mar 31, 2023 | 39.62 Mn |
| Dec 31, 2022 | 57.70 Mn |
| Sep 30, 2022 | 61.63 Mn |
| Jun 30, 2022 | 22.69 Mn |
| Mar 31, 2022 | 60.11 Mn |
| Dec 31, 2021 | 66.77 Mn |
| Sep 30, 2021 | 216.59 Mn |
API Access
Halozyme Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();